- Home
- GBIO vs ACCS Comparison
GBIO vs ACCS Comparison
Compare GBIO & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- ACCS
- Stock Information
- Founded
- GBIO 2016
- ACCS 1988
- Country
- GBIO United States
- ACCS United States
- Employees
- GBIO N/A
- ACCS N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- ACCS Publishing
- Sector
- GBIO Health Care
- ACCS Consumer Discretionary
- Exchange
- GBIO Nasdaq
- ACCS Nasdaq
- Market Cap
- GBIO 41.2M
- ACCS 42.6M
- IPO Year
- GBIO 2020
- ACCS N/A
- Fundamental
- Price
- GBIO $6.71
- ACCS N/A
- Analyst Decision
- GBIO Buy
- ACCS Strong Buy
- Analyst Count
- GBIO 4
- ACCS 1
- Target Price
- GBIO $10.67
- ACCS $14.00
- AVG Volume (30 Days)
- GBIO 39.3K
- ACCS 5.5K
- Earning Date
- GBIO 11-05-2025
- ACCS 11-06-2025
- Dividend Yield
- GBIO N/A
- ACCS N/A
- EPS Growth
- GBIO N/A
- ACCS N/A
- EPS
- GBIO N/A
- ACCS N/A
- Revenue
- GBIO $21,230,000.00
- ACCS $22,562,000.00
- Revenue This Year
- GBIO N/A
- ACCS $0.03
- Revenue Next Year
- GBIO N/A
- ACCS $11.45
- P/E Ratio
- GBIO N/A
- ACCS N/A
- Revenue Growth
- GBIO 61.15
- ACCS 26.44
- 52 Week Low
- GBIO $3.00
- ACCS $7.79
- 52 Week High
- GBIO $25.70
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- GBIO 65.83
- ACCS 29.80
- Support Level
- GBIO $6.08
- ACCS $9.51
- Resistance Level
- GBIO $6.48
- ACCS $10.90
- Average True Range (ATR)
- GBIO 0.33
- ACCS 0.30
- MACD
- GBIO -0.01
- ACCS -0.07
- Stochastic Oscillator
- GBIO 83.58
- ACCS 13.29
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.